The renaissance of interferon therapy for the treatment of myeloid malignancies

Issues of Imatinib and Pregnancy Outcome

(2017) Jane Apperley   Journal of the National Comprehensive Cancer Network

Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives

(2012) Hans Carl Hasselbalch et al.   CURRENT DRUG TARGETS

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Interferon-α as angiogenesis inhibitor: Learning from tumor models

(2010) Stefano Indraccolo   AUTOIMMUNITY

Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity

(2010) Paola Rizza et al.   AUTOIMMUNITY

Implications of Mutational Analysis for the Management of Patients With Gastrointestinal Stromal Tumors and the Application of Targeted Therapies

(2010) Agnieszka Wozniak et al.   CANCER INVESTIGATION

New Developments in Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed Chronic Myeloid Leukemia

(2010) P. le Coutre et al.   CLINICAL CANCER RESEARCH

Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway

(2010) Min Lu et al.   EXPERIMENTAL HEMATOLOGY

Interferon-  induces the growth inhibition of human T-cell leukaemia line Jurkat through p38  and p38 

(2010) W. H. Lee et al.   JOURNAL OF BIOCHEMISTRY

Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia

(2010) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Type I interferon: friend or foe?

(2010) Giorgio Trinchieri   JOURNAL OF EXPERIMENTAL MEDICINE

Jekyll and Hyde: the role of the microenvironment on the progression of cancer

(2010) Michael Allen et al.   JOURNAL OF PATHOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2 V617F clones without affecting TET2 mutant cells

(2010) J-J Kiladjian et al.   LEUKEMIA

Quiescent haematopoietic stem cells are activated by IFN-γ in response to chronic infection

(2010) Megan T. Baldridge et al.   NATURE

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal

(2010) Shreya Kanodia et al.   PLoS One

Resistance to Imatinib: Mutations and Beyond

(2010) Paul La Rosée et al.   SEMINARS IN HEMATOLOGY

Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?

(2010) Meetu Agrawal et al.   Current Oncology Reports

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine

(2009) Ken H. Lim et al.   AMERICAN JOURNAL OF HEMATOLOGY

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference

(2009) G. Barosi et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

PEG-IFN-α-2a therapy in patients with myelofibrosis

(2009) Jean-Christophe Ianotto et al.   BRITISH JOURNAL OF HAEMATOLOGY

Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation

(2009) Leonardo Potenza et al.   BRITISH JOURNAL OF HAEMATOLOGY

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

(2009) Thomas Stauffer Larsen et al.   Hematology

Role of Schlafen 2 (SLFN2) in the Generation of Interferon α-induced Growth Inhibitory Responses

(2009) Efstratios Katsoulidis et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of dasatinib in conjunction with α-interferon for the treatment of imatinib-resistant and dasatinib-resistant Ph+ acute lymphoblastic leukemia

(2009) G Visani et al.   LEUKEMIA

Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis

(2009) R T Silver et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

IFNα activates dormant haematopoietic stem cells in vivo

(2009) Marieke A. G. Essers et al.   NATURE

Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon–dependent exhaustion

(2009) Taku Sato et al.   NATURE MEDICINE

Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses

(2009) S. Joshi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The IRF Family Transcription Factors in Immunity and Oncogenesis

(2008) Tomohiko Tamura et al.   Annual Review of Immunology

Interferon- 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes

(2008) A. Yamane et al.   BLOOD

The effects of imatinib on pregnancy outcome

(2008) S. M. Pye et al.   BLOOD

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy

(2008) Martin Griesshammer et al.   BLOOD REVIEWS

Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update

(2008) R. Seggewiss et al.   CYTOTHERAPY

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome

(2008) F. Palandri et al.   HAEMATOLOGICA

Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms

(2008) J-J Kiladjian et al.   LEUKEMIA